Review: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

Home/Review: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

Review: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

Review: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

This randomized trial showed that hydroxychloroquine did not prevent presumed/confirmed COVID-19 when used as post-exposure prophylaxis within 4 days of high- or moderate-risk COVID-19 exposure.

  • This randomized, double-blind, placebo-controlled trial occurred across the United States and parts of Canada
  • Enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure).
  • Within 4 days after exposure, participants were randomly assigned to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days).
  • 821 asymptomatic participants were enrolled, most of whom (87.6) had a high-risk exposure
  • The incidence of presumed/confirmed COVID-19 within the 14 day follow-up period did not differ significantly between groups:
    • Hydroxychloroquine (49 of 414 [11.8%]) and Placebo (58 of 407 [14.3%])
    • Absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P=0.35).
  • Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported

 

|2020-06-04T09:41:30-04:00June 3rd, 2020|COVID-19 Literature|0 Comments

About the Author: Megan McHenry

Megan McHenry
Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya. Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Get Involved with Indiana CTSI